WNT6 is a novel target gene of caveolin-1 promoting chemoresistance to epirubicin in human gastric cancer cells

Oncogene

Volumn 32, Issue 3, 2013, Pages 375-387

  Yuan, G ^a,b   Regel, I ^a   Lian, F ^b   Friedrich, T ^a   Hitkova, I ^c   Hofheinz, R D ^c   Strobel P ^c   Langer, R ^a   Keller, G ^a   Rocken C ^d   Zimmermann, W ^e   Schmid, R M ^a   Ebert, M P A ^c   Burgermeister, E ^c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b SUN YAT SEN UNIVERSITY   (China)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY OF KIEL   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

caveolin; epirubicin; gastric cancer; stomach; WNT

Indexed keywords

ANTHRACYCLINE; BETA CATENIN; CAVEOLIN 1; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; WNT6 PROTEIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CAVEOLIN 1; CELL LINE, TUMOR; CONSERVED SEQUENCE; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TRANSCRIPTION FACTORS; WNT PROTEINS;

MOUSE MAMMARY TUMOR VIRUS; MURINAE;

EID: 84872617436     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.40     Document Type: Article

References (58)

1. Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003; 56: 1-9.
2. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010; 19: 1893-1907.
3. Becker K, Langer R, Reim D, Novotny A, Meyer Zum Buschenfelde C, Engel J et al. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg 2011; 253: 934-939.
4. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
5. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46.
6. Logan CY, Nusse R. The WNT signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004; 20: 781-810.
7. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006; 127: 469-480.
8. Wei Y, Fabre M, Branchereau S, Gauthier F, Perilongo G, Buendia MA. Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas. Oncogene 2000; 19: 498-504.
9. Taniguchi K, Roberts LR, Aderca IN, Dong X, Qian C, Murphy LM et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 2002; 21: 4863-4871.
10. Hadjihannas MV, Brückner M, Jerchow B, Birchmeier W, Dietmaier W, Behrens J. Aberrant WNT/beta-catenin signaling can induce chromosomal instability in colon cancer. Proc Natl Acad Sci USA 2006; 103: 10747-10752.
11. Asciutti S, Akiri G, Grumolato L, Vijayakumar S, Aaronson SA. Diverse mechanisms of WNT activation and effects of pathway inhibition on proliferation of human gastric carcinoma cells. Oncogene 2011; 30: 956-966.
12. Kikuchi A, Yamamoto H, Sato A. Selective activation mechanisms of Wnt signaling pathways. Trends Cell Biol 2009; 19: 119-129.
13. Kobune M, Chiba H, Kato J, Kato K, Nakamura K, Kawano Y et al. Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism. Mol Cancer Ther 2007; 6: 1774-1784.
14. Flahaut M, Meier R, Coulon A, Nardou KA, Niggli FK, Martinet D et al. The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway. Oncogene 2009; 28: 2245-2256.
15. Noda T, Nagano H, Takemasa I, Yoshioka S, Murakami M, Wada H et al. Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferonalpha/5-fluorouracil combination therapy for hepatocellular carcinoma. Br J Cancer 2009; 100: 1647-1658.
16. Nyeng P, Norgaard GA, Kobberup S, Jensen J. FGF10 signaling controls stomach morphogenesis. Dev Biol 2007; 303: 295-310.
17. Krawetz R, Kelly GM. WNT6 induces the specification and epithelialization of F9 embryonal carcinoma cells to primitive endoderm. Cell Signal 2008; 20: 506-517.
18. Kirikoshi H, Sekihara H, Katoh M. WNT10A and WNT6, clustered in human chromosome 2q35 region with head-to-tail manner, are strongly coexpressed in SW480 cells. Biochem Biophys Res Commun 2001; 283: 798-805.
19. Razani B, Woodman SE, Lisanti MP. Caveolae: from cell biology to animal physiology. Pharmacol Rev 2002; 54: 431-467.
20. Parton RG, Simons K. The multiple faces of caveolae. Nat Rev Mol Cell Biol 2007; 8: 185-194.
21. Anderson RG, Jacobson K. A role for lipid shells in targeting proteins to caveolae, rafts, and other lipid domains. Science 2002; 296: 1821-1825.
22. Williams TM, Lisanti MP. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol 2005; 288: C494-C506.
23. Burgermeister E, Xing X, Röcken C, Juhasz M, Chen J, Hiber M et al. Differential expression and function of caveolin-1 in human gastric cancer progression. Cancer Res 2007; 67: 8519-8526.
24. Lavie Y, Fiucci G, Liscovitch M. Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells. J Biol Chem 1998; 273: 32380-32383.
25. Yang CP, Galbiati F, Volonte D, Horwitz SB, Lisanti MP. Upregulation of caveolin-1 and caveolae organelles in Taxol-resistant A549 cells. FEBS Lett 1998; 439: 368-372.
26. Bélanger MM, Gaudreau M, Roussel E, Couet J. Role of caveolin-1 in etoposide resistance development in A549 lung cancer cells. Cancer Biol Ther 2004; 3: 954-959.
27. Ho CC, Kuo SH, Huang PH, Huang HY, Yang CH, Yang PC. Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy. Lung Cancer 2008; 59: 105-110.
28. Shatz M, Liscovitch M. Caveolin-1 and cancer multidrug resistance: coordinate regulation of pro-survival proteins? Leuk Res 2004; 28: 907-908.
29. Joo HJ, Oh DK, Kim YS, Lee KB, Kim SJ. Increased expression of caveolin-1 and microvessel density correlates with metastasis and poor prognosis in clear cell renal cell carcinoma. BJU Int 2004; 93: 291-296.
30. Barresi V, Cerasoli S, Paioli G, Vitarelli E, Giuffrè G, Guiducci G et al. Caveolin-1 in meningiomas: expression and clinico-pathological correlations. Acta Neuropathol 2006; 112: 617-626.
31. Karam JA, Lotan Y, Roehrborn CG, Ashfaq R, Karakiewicz PI, Shariat SF. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate 2007; 67: 614-622.
32. Du ZM, Hu CF, Shao Q, Huang MY, Kou CW, Zhu XF et al. Upregulation of caveolin-1 and CD147 expression in nasopharyngeal carcinoma enhanced tumor cell migration and correlated with poor prognosis of the patients. Int J Cancer 2009; 125: 1832-1841.
33. Burgermeister E, Friedrich T, Hitkova I, Gruner-Regel I, Einwächter H, Zimmermann W et al. The ras inhibitors caveolin-1 and docking protein-1 activate PPARgamma through spatial relocalization at helix-7 of its ligand-binding domain. Mol Cell Biol 2011; 31: 3497-3510.
34. Kang HC, Kim IJ, Park JH, Shin Y, Ku JL, Jung MS et al. Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using highdensity oligonucleotide microarrays. Clin Cancer Res 2004; 10: 272-284.
35. Burrus LM, McMahon AP. Biochemical analysis of murine WNT proteins reveals both shared and distinct properties. Exp Cell Res 1995; 220: 363-373.
36. Thompson J, Epting T, Schwarzkopf G, Singhofen A, Eades-Perner AM, van Der Putten H et al. A transgenic mouse line that develops early-onset invasive gastric gastric carcinoma provides a model for carcinoembryonic antigen-targeted tumor therapy. Int J Cancer 2000; 86: 863-869.
37. Bourquin C, von der Borch P, Zoglmeier C, Anz D, Sandholzer N, Suhartha N et al. Efficient eradication of subcutaneous but not of autochthonous gastric tumors by adoptive T cell transfer in an SV40 T antigen mouse model. J Immunol 2010; 185: 2580-2588.
38. Becker K, Muller JD, Schulmacher C, Ott K, Fink U, Busch R et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003; 98: 1521-1530.
39. Hausmann G, Bänziger C, Basler K. Helping Wingless take flight: how WNT proteins are secreted. Nat Rev Mol Cell Biol 2007; 8: 331-336.
40. Conner SD, Schmid SL. Regulated portals of entry into the cell. Nature 2003; 422: 37-44.
41. Yamamoto H, Komekado H, Kikuchi A. Caveolin is necessary for WNT-3adependent internalization of LRP6 and accumulation of beta-catenin. Dev Cell 2006; 11: 213-223.
42. Bilic J, Huang YL, Davidson G, Zimmermann T, Cruciat CM, Bienz M et al. WNT induces LRP6 signalosomes and promotes dishevelled-dependent LRP6 phosphorylation. Science 2007; 316: 1619-1622.
43. Galbiati F, Volonte D, Brown AM, Weinstein DE, Ben-Ze'ev A, Pestell RG et al. Caveolin-1 expression inhibits WNT/beta-catenin/Lef-1 signaling by recruiting beta-catenin to caveolae membrane domains. J Biol Chem 2000; 275: 23368-23377.
44. Dvory-Sobol H, Sagiv E, Liberman E, Kazanov D, Arber N. Suppression of gastric cancer cell growth by targeting the beta-catenin/T-cell factor pathway. Cancer 2007; 109: 188-197.
45. Huang J, Yang J, Maity B, Mayuzumi D, Fisher RA. Regulator of G protein signaling 6 (RGS6) mediates doxorubicin-induced ATM and p53 activation by a reactive oxygen species (ROS)-dependent mechanism. Cancer Res 2011; 71: 6310-6319.
46. Millour J, de Olano N, Horimoto Y, Monteiro LJ, Langer JK, Aligue R et al. ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance. Mol Cancer Ther 2011; 10: 1046-1058.
47. Bist A, Fielding CJ, Fielding PE. p53 regulates caveolin gene transcription, cell cholesterol, and growth by a novel mechanism. Biochemistry 2000; 39: 1966-1972.
48. Li Q, Lin S, Wang X, Lian G, Lu Z, Guo H et al. Axin determines cell fate by controlling the p53 activation threshold after DNA damage. Nat Cell Biol 2009; 11: 1128-1134.
49. Lee KH, Li M, Michalowski AM, Zhang X, Liao H, Chen L et al. A genomewide study identifies the Wnt signaling pathway as a major target of p53 in murine embryonic stem cells. Proc Natl Acad Sci USA 2010; 107: 69-74.
50. Goetz JG, Lajoie P, Wiseman SM, Nabi IR. Caveolin-1 in tumor progression: the good, the bad and the ugly. Cancer Metastasis Rev 2008; 27: 715-735.
51. Kurayoshi M, Oue N, Yamamoto H, Kishida M, Inoue A, Asahara T et al. Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion. Cancer Res 2006; 66: 10439-10448.
52. Yamamoto H, Kitadai Y, Yamamoto H, Oue N, Ohdan H, Yasui W et al. Laminin gamma2 mediates Wnt5a-induced invasion of gastric cancer cells. Gastroenterology 2009; 137: 242-252.
53. Ordway JM, Bedell JA, Citek RW, Nunberg A, Garrido A, Kendall R et al. Comprehensive DNA methylation profiling in a human cancer genome identifies novel epigenetic targets. Carcinogenesis 2006; 27: 2409-2423.
54. Fiucci G, Ravid D, Reich R, Liscovitch M. Caveolin-1 inhibits anchorageindependent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene 2002; 21: 2365-2375.
55. Ravid D, Maor S, Werner H, Liscovitch M. Caveolin-1 inhibits cell detachmentinduced p53 activation and anoikis by upregulation of insulin-like growth factor-1 receptors and signaling. Oncogene 2005; 24: 1338-1347.
56. Chen J, Röcken C, Hoffmann J, Krüger S, Lendeckel U, Rocco A et al. Expression of carbonic anhydrase 9 at the invasion front of gastric cancers. Gut 2005; 54: 920-927.
57. Ebert MP, Fei G, Kahmann S, Müller O, Yu J, Sung JJ et al. Increased beta-catenin mRNA levels and mutational alterations of the APC and beta-catenin gene are present in intestinal-type gastric cancer. Carcinogenesis 2002; 23: 87-91.
58. Burgermeister E, Schnoebelen A, Flament A, Benz J, Stihle M, Gsell B et al. A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro. Mol Endocrinol 2006; 20: 809-830.